Approvals
- Alert Advagraf 0.5-mg Capsules Recalled by EMA
- FDA Okays 2 Lower-Strength Testosterone Patches
- Alert FDA Updates Warnings on Methylene Blue, Linezolid, and Serotonergics
- FDA Approves Deferiprone for Iron Overload
- Alert Dasatinib May Raise Risk for Pulmonary Arterial Hypertension
- FDA Approves Inhalation Spray for COPD
- Tadalafil Approved for Benign Prostatic Hyperplasia
- New Bevacizumab Label Includes Risk for Ovarian Failure
- Gel to Control Bleeding During Surgery Gets FDA Nod
- Linagliptin Approved in Canada for Type 2 Diabetes
- Diaphragm Pacing System Gets FDA Nod for ALS
- Alert FDA Still 'Concerned' About Drospirenone VTE Risk
- FDA Okays Infliximab for Pediatric Ulcerative Colitis
- Eculizumab Approved for Rare Pediatric Blood Disorder
- Telaprevir Receives European Approval
- Europe Approves Telavancin for Hospital-Acquired Pneumonia
- FDA Approves Denosumab for Patients With Cancer
- Alert Qualitest Oral Contraceptives Recalled
- Orphan Drug Status for Corneal Cross-Linking in Keratoconus
- Health Canada Approves Everolimus for Pediatric Brain Tumors